Last 30 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.08 | — | — | — | — | 0.90 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.23 | 3.47 | 0.90 | 0.68 | 1.92 | 0.17 | 20.95 | 3.68 | 17.47 | 36.68 | 31.30 | 24.33 | 12.58 |
| — | +1897.9% | -95.7% | -81.5% | -89.0% | -99.5% | -33.0% | -84.9% | +38.8% | -67.1% | -94.1% | -87.4% | -95.2% | |
| P/B Ratio | 0.19 | 7.82 | 1.60 | 1.32 | 2.96 | 0.36 | 10.30 | 1.32 | — | 55.18 | 16.19 | — | — |
| — | +2067.6% | -84.4% | +0.2% | — | -99.3% | -36.4% | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | -0.52 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | -0.52 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Ensysce Biosciences, Inc.'s operating margin was -758.7% in Q3 2025, down 631.0 pp QoQ and down 777.5 pp YoY. The trailing four-quarter average of -327.4% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 1087.7% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -38.6% | -499.2% | -40.2% | 100.0% | -191.7% | 50.5% | -421.0% | -154.7% | -333.5% | -339.8% | -235.1% | -127.4% | -349.4% |
| — | -1087.7% | +90.4% | +164.6% | +42.5% | +114.9% | -79.1% | -21.4% | +4.5% | +78.8% | +90.4% | +69.7% | -934.0% | |
| Operating Margin | -129.2% | -758.7% | -127.6% | -149.1% | -274.3% | 18.9% | -1075.6% | -602.8% | -612.7% | -621.8% | -467.7% | -324.4% | -432.6% |
| — | -4123.0% | +88.1% | +75.3% | +55.2% | +103.0% | -130.0% | -85.9% | -41.6% | +71.8% | +86.2% | +59.3% | -252.5% | |
| Net Margin | -153.3% | -756.3% | -126.4% | -147.4% | -273.4% | 19.4% | -1082.4% | -1019.2% | -680.2% | -617.8% | -455.1% | -277.1% | -383.0% |
| — | -4007.0% | +88.3% | +85.5% | +59.8% | +103.1% | -137.8% | -267.9% | -77.6% | +82.5% | +88.2% | -75.7% | +37.6% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -585.4% | -189.5% | -60.0% | -63.8% | -71.6% | 16.4% | -80.3% | -225.0% | -1383.6% | -108.7% | -122.6% | — | — |
| — | -1254.1% | +25.3% | +71.6% | +94.8% | +115.1% | +34.5% | — | — | — | +97.6% | — | — | |
| ROA | -192.3% | -85.2% | -34.0% | -38.1% | -47.6% | 10.9% | -50.0% | -80.1% | -118.2% | -56.2% | -43.5% | -44.7% | -77.5% |
| — | -884.1% | +31.9% | +52.4% | +59.8% | +119.3% | -15.1% | -79.3% | -52.6% | +53.6% | +44.8% | -575.8% | -0.9% | |
| ROIC | — | -668.9% | -219.0% | -2813.3% | -179.3% | 26.1% | -254.4% | — | — | -869.7% | — | — | — |
| — | -2661.8% | +13.9% | — | — | +103.0% | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 60.8% YoY to 1.27x, tightening the short-term liquidity position. Debt/Equity has risen for 5 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.42 | 0.14 | 0.09 | 0.09 | 0.06 | 0.31 | 0.07 | — | 0.31 | 0.12 | — | — |
| — | +607.3% | -54.8% | +31.6% | — | -80.7% | +155.1% | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | 0.58 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.42 | 1.27 | 2.10 | 2.50 | 2.42 | 3.24 | 1.88 | 2.87 | 0.69 | 1.36 | 2.33 | 0.85 | 0.56 |
| — | -60.8% | +11.6% | -12.9% | +252.6% | +138.9% | -19.1% | +238.6% | +22.6% | +111.1% | +166.7% | -36.0% | -41.1% | |
| Quick Ratio | 2.42 | 1.27 | 2.10 | 2.50 | 2.42 | 3.24 | 1.88 | 2.87 | 0.69 | 1.36 | 2.33 | 0.85 | 0.56 |
| — | -60.8% | +11.6% | -12.9% | +252.6% | +138.9% | -19.1% | +238.6% | +22.6% | +111.1% | +166.7% | -36.0% | -41.1% | |
| Interest Coverage | -5.22 | -587.39 | -553.96 | -510.37 | -332.60 | 158.73 | -70.94 | -1.48 | -9.15 | -353.94 | — | -1710.91 | -5.21 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying ENSC stock.
Ensysce Biosciences, Inc.'s current P/E is -0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Ensysce Biosciences, Inc.'s current operating margin is -129.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Ensysce Biosciences, Inc.'s business trajectory between earnings reports.